Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 1
Submit an article Journal homepage
191
Views
13
CrossRef citations to date
0
Altmetric
Review

Role of dihydropyridinic calcium channel blockers in the management of hypertension

Antonio Coca Department of Internal Medicine, Hypertension Unit, Institute of Medicine & Dermatology, Hospital Clínico, University of Barcelona, Barcelona, Spain. [email protected]; Department of Internal Medicine, Hypertension Unit, Institute of Medicine & Dermatology, Hospital Clínico, University of Barcelona, Barcelona, Spain. [email protected]
,
Pilar Mazón Department of Cardiology, Hospital Clínico Universitario, Santiago de Compostela, A Coruña, Spain; Department of Cardiology, Hospital Clínico Universitario, Santiago de Compostela, A Coruña, Spain
,
Pedro Aranda Hypertension and Vascular Risk Unit, Hospital General Universitario Carlos Haya, Málaga, Spain; Hypertension and Vascular Risk Unit, Hospital General Universitario Carlos Haya, Málaga, Spain
,
Josep Redón Department of Internal Medicine, Hypertension Unit, Hospital Clínico Universitario, Valencia, Spain; Department of Internal Medicine, Hypertension Unit, Hospital Clínico Universitario, Valencia, Spain
,
Juan Antonio Divisón Primary Care Center Casas Ibañez, Albacete, Spain; Primary Care Center Casas Ibañez, Albacete, Spain
,
Javier Martínez Department of Endocrinology, Hospital General de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Canary Islands, Spain; Hypertension and Vascular Risk Unit, Hospital Clínico Universitario, Santiago de Compostela, A Coruña, Spain
,
Carlos Calvo Hypertension and Vascular Risk Unit, Hospital Clínico Universitario, Santiago de Compostela, A Coruña, Spain; Hypertension and Vascular Risk Unit, Hospital Clínico Universitario, Santiago de Compostela, A Coruña, Spain
,
Josep María Galcerán Department of Nephrology, Fundacion Althaia, Manresa, Barcelona, Spain; Department of Nephrology, Fundacion Althaia, Manresa, Barcelona, Spain
,
Vivencio Barrios Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain; Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain
&
Alexandre Roca-Cusachs i Coll Department of Internal Medicine, Hypertension Unit, Hospital Sant Pau, Universidad Autónoma de Barcelona, Barcelona, Spain; Department of Internal Medicine, Hypertension Unit, Hospital Sant Pau, Universidad Autónoma de Barcelona, Barcelona, Spain
 show all
Pages 91-105 | Published online: 10 Jan 2014

References

  • Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J. Hypertens. 22(1), 11–19 (2004).
  • Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens. 21(6), 1055–1076 (2003).
  • Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121–2158 (2009).
  • Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs 65(Suppl. 2), 1–10 (2005).
  • Beltrame JF, Turner SP, Leslie SL, Solomon P, Freedman SB, Horowitz JD. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. J. Am. Coll. Cardiol. 44(1), 57–62 (2004).
  • Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ. Res. 100(3), 342–353 (2007).
  • Spedding M, Paoletti R. Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol. Rev. 44(3), 363–376 (1992).
  • Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 290(2), 199–206 (2003).
  • Thomas F, Rudnichi A, Bacri AM, Bean K, Guize L, Benetos A. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 37(5), 1256–1261 (2001).
  • Mancia G, De Backer G, Dominiczak A et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105–1187 (2007).
  • Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009).
  • Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350(9080), 757–764 (1997).
  • Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J. Hypertens. 16(12 Pt 1), 1823–1829 (1998).
  • Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am. J. Hypertens. 14(3), 241–247 (2001).
  • Neutel JM, Smith DH, Wallin D et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am. J. Hypertens. 7(7 Pt 1), 623–628 (1994).
  • Neaton JD, Primeas RJ, Flack JM et al. Long-term antihypertensive effect of different classes of antihypertensive drugs in mild hypertension: Treatment of Mild Hypertension Study (TOMHS). JAMA 270(6), 713–724 (1993).
  • Fogari R, Zoppi A, Corradi L, Preti P, Malalamani GD, Mugellini A. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J. Hypertens. 18(12), 1871–1875 (2000).
  • Payeras AC, Sladek K, Lembo G, Alberici M. Antihypertensive Efficacy and Safety of Manidipine Versus Amlodipine in Elderly Subjects with Isolated Systolic Hypertension: MAISH study. Clin. Drug Investig. 27(9), 623–632 (2007).
  • Richy FF, Laurent S. Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials. Blood Press. 20(1), 54–59 (2011).
  • Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895–906 (2005).
  • Julius S, Kjeldsen SE, Weber M et al.; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363(9426), 2022–2031 (2004).
  • Ogihara T, Nakao K, Fukui T et al.; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension 51(2), 393–398 (2008).
  • Roca-Cusachs A, Triposkiadis F. Antihypertensive effect of manidipine. Drugs 65(Suppl. 2), 11–19 (2005).
  • Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404), 1427 (2003).
  • Williams B, Lacy PS, Thom SM et al.; CAFE Investigators; Anglo–Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113(9), 1213–1225 (2006).
  • Saunders E, Weir MR, Kong BW et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch. Intern. Med. 150(8), 1707–1713 (1990).
  • Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med. 328(13), 914–921 (1993).
  • Neutel JM. The use of combination drug therapy in the treatment of hypertension. Prog. Cardiovasc. Nurs. 17(2), 81–88 (2002).
  • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981–2997 (2002).
  • Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351(9118), 1755–1762 (1998).
  • Dahlöf B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 995–1003 (2002).
  • Lewis EJ, Hunsicker LG, Clarke WR et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345(12), 851–860 (2001).
  • Cushman WC, Ford CE, Cutler JA et al.; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. (Greenwich) 4(6), 393–404 (2002).
  • Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417–2428 (2008).
  • Philipp T, Smith TR, Glazer R et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin. Ther. 29(4), 563–580 (2007).
  • Poldermans D, Glazes R, Kargiannis S et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther. 29(2), 279–289 (2007).
  • Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122(3), 290–300 (2009).
  • Malacco E, Varì N, Capuano V, Spagnuolo V, Borgnino C, Palatini P; Val-Syst study. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin. Ther. 25(11), 2765–2780 (2003).
  • Epstein M. Calcium antagonists in the management of hypertension. In: Calcium Antagonists in Clinical Medicine. Epstein M (Ed.). Hanley and Belfus Inc., PA, USA, 293–313 (2002).
  • Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am. J. Hypertens. 14(9 Pt 1), 963–968 (2001).
  • Messerli FH. Combinations in the treatment of hypertension: ACE inhibitors and calcium antagonists. Am. J. Hypertens. 12(8 Pt 2), S86–S90 (1999).
  • Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am. J. Hypertens. 15(6), 550–556 (2002).
  • Fogari R, Malamani GD, Savino S et al. Effects of different dihydropyridine calcium antagonists on pretibial subcutaneous tissue pressure in hypertensive patients. Am. J. Hypertens. 11(Suppl. 3) (1998) (Abstract 114A).
  • Tikhonoff V, Mazza A, Casiglia E. Differential effects of manidipine and lercanidipine on blood pressure, peripheral circulation and ankle oedema in hypertensive patients. J. Hypertens. 22(Suppl. 2) (2004)(Abstract 244A).
  • Pavlicevi I, Kuzmani M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and non-steroidal anti-inflammatory drugs in primary care: a controlled trial. Can. J. Clin. Pharmacol. 15(3), e372–e382 (2008).
  • Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274(8), 620–625 (1995).
  • Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92(5), 1326–1331 (1995).
  • Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am. J. Hypertens. 9(7), 695–699 (1996).
  • Braun S, Boyko V, Behar S et al. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. J. Am. Coll. Cardiol. 28(1), 7–11 (1996).
  • Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 356(9246), 1955–1964 (2000).
  • Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 67(9), 1309–1327 (2007).
  • Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362(9395), 1527–1535 (2003).
  • Packer M, O’Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N. Engl. J. Med. 335(15), 1107–1114 (1996).
  • Costanzo P, Perrone-Filardi P, Petretta M et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J. Hypertens. 27(6), 1136–1151 (2009).
  • Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322(22), 1561–1566 (1990).
  • Barrios V, Escobar C, Calderon A, Ribas L, Marti D, Asin E. Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population. Blood Press. 17(2), 110–115 (2008).
  • Barrios V, Calderón A, Escobar C et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study. J. Hypertens. 25(9), 1967–1973 (2007).
  • Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am. J. Hypertens. 16(11 Pt 1), 895–899 (2003).
  • Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 115(1), 41–46 (2003).
  • Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 54(5), 1084–1091 (2009).
  • Grobbee DE, Bots ML. Carotid artery intima–media thickness as an indicator of generalized atherosclerosis. J. Intern. Med. 236(5), 567–573 (1994).
  • Simon A, Gariépy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 103(24), 2949–2954 (2001).
  • Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 102(13), 1503–1510 (2000).
  • Zanchetti A, Bond MG, Hennig M et al.; ELSA Investigators. Absolute and relative changes in carotid intima–media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). J. Hypertens. 22(6), 1201–1212 (2004).
  • ENCORE Investigators. Effects of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease. The ENCORE I Study (Evaluation of Nifedipine and Cerivastatin on Recovery of Coronary Endothelial Function). Circulation 107(3), 422–428 (2003).
  • Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler. Thromb. Vasc. Biol. 23(12), 2155–2163 (2003).
  • Ishii N, Matsumura T, Shimoda S, Araki E. Anti-atherosclerotic potential of dihydropyridine calcium channel blockers. J. Atheroscler. Thromb. 19(8), 693–704 (2012).
  • Preston Mason R. Pleiotropic effects of calcium channel blockers. Curr. Hypertens. Rep. 14(4), 293–303 (2012).
  • Buset Ríos N, Rodríguez Esparragón F, Fernández-Andrade Rodríguez C, Rodríguez Pérez JC. [Vascular and metabolic properties of manidipine.] Nefrologia 31(3), 268–274 (2011).
  • Hillege HL, Fidler V, Diercks GF et al.; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106(14), 1777–1782 (2002).
  • Wright JT Jr, Bakris G, Greene T et al.; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288(19), 2421–2431 (2002).
  • Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int. 53(6), 1559–1573 (1998).
  • Jafar TH, Stark PC, Schmid CH et al.; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. 139(4), 244–252 (2003).
  • Bakris GL. Maximizing cardiorenal benefit in the management of hypertension: achieve blood pressure goals. J. Clin. Hypertens. (Greenwich) 1(2), 141–147 (1999).
  • Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J. Am. Soc. Nephrol. 16(10), 3027–3037 (2005).
  • Bakris GL, Sarafidis PA, Weir MR et al.; ACCOMPLISH Trial Investigators. Renal Outcomes with Different Fixed-Dose Combination Therapies in Patients with Hypertension at High Risk for Cardiovascular Events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375(9721), 1173–1181 (2010).
  • Jafar TH, Stark PC, Schmid CH et al.; AIPRD Study Group. Angiotensin-converting enzyme inhibition and progression of renal disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 60(3), 1131–1140 (2001).
  • Fogari R, Preti P, Zoppi A et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive Type 2 diabetic patients. Am. J. Hypertens. 15(12), 1042–1049 (2002).
  • Nakagawa N, Fujino T, Kabara M et al.; NICE-Combi Study Group. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate. Hypertens. Res. 34(10), 1121–1126 (2011).
  • Furukawa T, Nukada T, Miura R et al. Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (α-1G) expressed in Xenopus oocytes. J. Cardiovasc. Pharmacol. 45(3), 241–246 (2005).
  • Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T. Role of actions of calcium antagonists on efferent arterioles – with special references to glomerular hypertension. Am. J. Nephrol. 23(4), 229–244 (2003).
  • Martinez-Martin FJ, Saiz-Satjes M. Add-on Manidipine Versus Amlodipine in Diabetic Patients with Hypertension and Microalbuminuria: the AMANDHA study. Expert Rev. Cardiovasc. Ther. 6(10), 1347–1355 (2008).
  • Alberti KG, Eckel RH, Grundy SM et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640–1645 (2009).
  • Cameron A. The metabolic syndrome: validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction. Maturitas 65(2), 117–121 (2010).
  • Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34(6), 416–422 (1991).
  • Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Engl. J. Med. 321(13), 868–873 (1989).
  • Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J. Hypertens. 7(7), 551–559 (1989).
  • Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201–207 (2007).
  • Tuomilehto J, Rastenyte D, Birkenhäger WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med. 340(9), 677–684 (1999).
  • Weber MA, Bakris GL, Jamerson K et al.; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J. Am. Coll. Cardiol. 56(1), 77–85 (2010).
  • Ruggenenti P, Lauria G, Iliev IP et al.; DEMAND Study Investigators. Effects of manidipine and delapril in hypertensive patients with Type 2 diabetes mellitus: the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial. Hypertension 58(5), 776–783 (2011).
  • Martínez Martín FJ. Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. Expert Rev. Cardiovasc. Ther. 7(7), 863–869 (2009).
  • Suzuki M, Kanazawa A, Hasegawa M, Harano Y. Improvement of insulin resistance in essential hypertension by long-acting Ca antagonist benidipine. Clin. Exp. Hypertens. 21(8), 1327–1344 (1999).
  • Martinez-Martin FJ, Macias-Batista A, Comi-Diaz C, Rodriguez-Rosas H, Soriano-Perera P, Pedrianes-Martin P. Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. Clin. Drug Investig. 31(3), 201–212 (2011).
  • Nakami T. PPAR-gamma activation by manidipine mediates enhanced adiponectin production and insulin sensitivity. J. Hypertens. 24(Suppl. 6), S161 (2006).
  • Martell-Claros N, de la Cruz JJ. Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study. Clin. Drug Investig. 31(6), 427–434 (2011).
  • Koh KK, Quon MJ, Lee SJ et al. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension. Diabetes Care 30(6), 1605–1607 (2007).
  • Blacher J, Staessen JA, Girerd X et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch. Intern. Med. 160(8), 1085–1089 (2000).
  • Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355(9207), 865–872 (2000).
  • Chobanian AV, Bakris GL, Black HR et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289(19), 2560–2572 (2003).
  • Turnbull F, Neal B, Ninomiya T et al.; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336(7653), 1121–1123 (2008).
  • Di Bari M, Pahor M, Franse LV et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial. Am. J. Epidemiol. 153(1), 72–78 (2001).
  • Wang JG, Staessen JA, Li Y et al. Carotid intima–media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 37(7), 1933–1940 (2006).
  • Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903–1913 (2002).
  • Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363(9426), 2049–2051 (2004).
  • Leenen FH, Nwachuku CE, Black HR et al.; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48(3), 374–384 (2006).
  • Nissen SE, Tuzcu EM, Libby P et al.; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292(18), 2217–2225 (2004).
  • Poole-Wilson PA, Lubsen J, Kirwan BA et al.; Coronary Disease Trial Investigating Outcome with Nifedipine Gastrointestinal Therapeutic System Investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 364(9437), 849–857 (2004).
  • Dargie HJ, Ford I, Fox KM; Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur. Heart J. 17(1), 104–112 (1996).
  • Pepine CJ, Handberg EM, Cooper-DeHoff RM et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290(21), 2805–2816 (2003).
  • Lloyd-Jones D, Adams R, Carnethon M et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3), 480–486 (2009).
  • Khan NA, Hemmelgarn B, Herman RJ et al.; Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 – therapy. Can. J. Cardiol. 25(5), 287–298 (2009).
  • Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J. Hypertens. 23(12), 2157–2172 (2005).
  • Schrader J, Lüders S, Kulschewski A et al.; MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 36(6), 1218–1226 (2005).
  • PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 358(9287), 1033–1041 (2001).
  • Lithell H, Hansson L, Skoog I et al.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 21(5), 875–886 (2003).
  • Verdecchia P, Reboldi G, Angeli F et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46(2), 386–392 (2005).
  • Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 375(9718), 906–915 (2010).
  • Galceran J, Plana J, Felip A, Pou G, Vila J, Sobrino J. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin–angiotensin system blockers. Expert Rev. Cardiovasc. Ther. 8(6), 751–757 (2010).
  • Ertel EA, Campbell KP, Harpold MM et al. Nomenclature of voltage-gated calcium channels. Neuron 25(3), 533–535 (2000).
  • Koichi H, Koichiro H, Shu W et al. T-type Ca channel blockade as a determinant of kidney protection. Keio. J. Med. 59(3), 84–95 (2010).
  • Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67(5), 600–606 (2010).
  • Kai T, Kuzumoto Y. Effects of a dual L/N-type calcium channel blocker cilnidipine on blood pressure, pulse rate, and autonomic functions in patients with mild to moderate hypertension. Clin. Exp. Hypertens. 31(7), 595–604 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.